{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:57:24Z","timestamp":1783414644027,"version":"3.54.6"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Hereditary cancer syndromes (HCS) are responsible for up to 10% of all cancers. At present, the majority of cancer susceptibility testing is initiated after a cancer diagnosis. There exists a significant opportunity for primary care providers including general obstetrician-gynecologists to engage in hereditary cancer risk assessment through adequate family history evaluation, initiation of genetic testing, and following the recommendations of national organizations. Identifying hereditary cancer genes may prompt primary prevention efforts such as enhanced screening, prevention, or personalized care strategies. We will review the literature regarding the approach and assessment of the most common gynecologic HCS.<\/jats:p>","DOI":"10.1097\/grf.0000000000000894","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:01:05Z","timestamp":1728291665000},"page":"660-665","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Genetic Predisposition for Gynecologic Cancers"],"prefix":"10.1097","volume":"67","author":[{"given":"Tavia","family":"Gonz\u00e1lez Pe\u00f1a","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Comprehensive Cancer Center, University of Virginia Health, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J Clin Oncol"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/AOG.0000000000003562","article-title":"Hereditary cancer syndromes and risk assessment: Acog Committee Opinion, Number 793","volume":"134","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ogc.2021.11.005","article-title":"Hereditary breast and ovarian cancer: an updated primer for OB\/GYNs","volume":"49","author":"Bellcross","year":"2022","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"106257","DOI":"10.1016\/j.cct.2020.106257","article-title":"Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care","volume":"101","author":"Bowen","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.22.00303","article-title":"Cascade testing for hereditary cancer syndromes: should we move toward direct relative contact? A systematic review and meta-analysis","volume":"40","author":"Frey","year":"2022","journal-title":"J Clin Oncol"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"100662","DOI":"10.1016\/j.gore.2020.100662","article-title":"Effects of initiating physician-performed germline testing in safety net clinic patients with epithelial ovarian cancer","volume":"34","author":"Jordan","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2017.73.6314","article-title":"National estimates of genetic testing in women with a history of breast or ovarian cancer","volume":"35","author":"Childers","year":"2017","journal-title":"J Clin Oncol"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2015.65.9557","article-title":"Randomized noninferiority trial of telephone delivery of BRCA1\/2 genetic counseling compared with in-person counseling: 1-year follow-up","volume":"34","author":"Kinney","year":"2016","journal-title":"J Clin Oncol"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jamaoncol.2023.3748","article-title":"Remotely delivered cancer genetic testing in the Making Genetic Testing Accessible (MAGENTA) Trial: a randomized clinical trial","volume":"9","author":"Swisher","year":"2023","journal-title":"JAMA Oncol"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amepre.2014.01.002","article-title":"Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 National Health Interview Surveys","volume":"46","author":"Mai","year":"2014","journal-title":"Am J Prev Med"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"e23523","DOI":"10.2196\/23523","article-title":"Barriers and facilitators to genetic service delivery models: scoping review","volume":"10","author":"Raspa","year":"2021","journal-title":"Interact J Med Res"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"1127683","DOI":"10.3389\/fonc.2023.1127683","article-title":"Updates in gynecologic care for individuals with lynch syndrome","volume":"13:","author":"Underkofler","year":"2021","journal-title":"Front Oncol"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S1470-2045(21)00580-5","article-title":"Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study","volume":"22","author":"de Andrade","year":"2021","journal-title":"Lancet Oncol"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"e239705","DOI":"10.1001\/jamanetworkopen.2023.9705","article-title":"Longitudinal analysis of cancer risk in children and adults with germline PTEN variants","volume":"6","author":"Yehia","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"658842","DOI":"10.3389\/fmed.2021.658842","article-title":"The skin in Cowden syndrome","volume":"8","author":"Lim","year":"2021","journal-title":"Front Med"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/ijgc-2022-003987","article-title":"Gynecologic manifestations of Peutz-Jeghers syndrome","volume":"33","author":"Bhardwaj","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2019181814","article-title":"BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations","volume":"291","author":"Elezaby","year":"2019","journal-title":"Radiology"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.14694\/EdBook_AM.2015.35.e50","article-title":"Addressing barriers to uptake of breast cancer chemoprevention for patients and providers","volume":"35","author":"Crew","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1245\/s10434-021-10445-9","article-title":"How protective are nipple-sparing prophylactic mastectomies in BRCA1 and BRCA2 mutation carriers?","volume":"28","author":"Garstka","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamasurg.2017.3422","article-title":"Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study","volume":"153","author":"Jakub","year":"2018","journal-title":"JAMA Surg"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"R30-20250512","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/GRF.0000000000000499","article-title":"Preventing ovarian cancer in high-risk women: one surgery at a time","volume":"63","author":"Swanson","year":"2020","journal-title":"Clin Obstet Gynecol"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:08:12Z","timestamp":1747062492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000894","relation":{},"ISSN":["0009-9201","1532-5520"],"issn-type":[{"value":"0009-9201","type":"print"},{"value":"1532-5520","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}